5/4/2021 7:11:20 AM
Incyte Q1 Non-GAAP EPS $0.67 Vs Loss $2.86 Last Year
4/26/2021 8:00:55 AM
William Blair Reiterates Incyte Corporation (INCY) At Outperform
4/23/2021 10:04:18 AM
Lilly : OLUMIANT Shows Improvements In Severity And Extent Of Atopic Dermatitis In Phase 3 Study Analyses
4/20/2021 6:47:32 AM
Lilly, Incyte Reports Results From Second Phase 3 Trial (BRAVE-AA1) Of Baricitinib In Adults With Severe Alopecia Areata
4/19/2021 4:21:31 PM
MorphoSys, Incyte Announce First Patient Dosed In Phase 3 InMIND Study
4/8/2021 6:47:35 AM
Lilly, Incyte: Phase 3 COV-BARRIER Study Of Baricitinib Fails To Meet Statistical Significance On Primary Endpoint
3/3/2021 6:47:12 AM
Lilly : Phase 3 Study On Baricitinib Meets Primary Endpoint Of Hair Regrowth Across Both Dosing Regimens
2/9/2021 7:11:33 AM
Incyte Q4 GAAP EPS $0.68; Non-GAAP EPS $0.93